查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1599717

BETA-內醯胺藥物和BETA-內醯胺酶抑制劑市場：按藥物類別、疾病、給藥途徑、分銷管道、最終用戶、藥物類型 - 2025-2030 年全球預測

Beta Lactam & Beta Lactamase Inhibitors Market by Drug Class, Disease, Route of Administration, Distribution Channels, End User, Drug Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年BETA-內醯胺藥物/BETA-內醯胺酶抑制劑市值為263.3億美元，預計2024年將達273.3億美元，複合年成長率為4.58%，預計2030年將達263.3億美元。萬美元。

BETA-內醯胺和BETA-內醯胺酶抑制劑市場的重點是抗生素，包括BETA-內醯胺抗生素和BETA-內醯胺酶抑制劑，它們針對併中和賦予細菌抗藥性的酶，這對於對抗細菌感染至關重要。抗生素抗藥性細菌帶來的全球挑戰凸顯了對這些化合物的需求，推動了醫療和製藥領域對治療各種細菌感染疾病的應用的需求。最終用途包括醫院、診所和居家照護，大部分需求發生在擁有成熟醫療基礎設施的地區。影響該市場的關鍵成長要素包括抗生素抗藥性感染疾病的增加、醫療保健成本的增加以及持續研究和開發新的製劑和組合藥物以提高療效。機會還存在於擴大負擔得起的醫療服務、政府遏制抗生素抗藥性的努力以及在藥物開發中採用先進生物技術。然而，嚴格的法律規範、藥物開發相關的高成本以及抗生素的潛在副作用可能會阻礙廣泛使用，並對市場開拓構成挑戰。創新的最佳領域包括開發具有頻譜活性和最小副作用的下一代BETA-內醯胺藥物，以及尋找協同效應組合以提高治療效率。對早期檢測抗藥性菌株的診斷工具的投資也可以推動市場需求。此外，鼓勵製藥公司和研究機構之間的合作可以更深入地了解抗藥性細菌，並有可能帶來突破性的解決方案。市場動態是動態的，其特點是快速發展和激烈競爭，要求相關人員透過在產品開拓和市場滲透策略方面的持續創新和策略規劃來保持領先地位。

主要市場統計
基準年[2023] 263.3億美元
預測年份 [2024] 273.3億美元
預測年份 [2030] 360.2億美元
複合年成長率（%） 4.58%

市場動態：快速發展的 BETA-內醯胺藥物和 BETA-內醯胺酶抑制劑市場的關鍵市場洞察

由於供需之間的動態相互作用，BETA-內醯胺藥物和BETA-內醯胺酶抑制劑的市場正在經歷轉型。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球細菌感染疾病增加
    • 政府打擊抗生素抗藥性的措施和計劃
    • 提高醫療保健專業人員和患者對抗生素聯合治療益處的認知
  • 市場限制因素
    • 嚴格的監管要求和漫長的新藥認證流程
  • 市場機會
    • 開發與BETA-內醯胺抗生素合併使用的新型BETA-內醯胺酶抑制劑
    • 減少抗生素生產對環境影響的永續生產方法
  • 市場挑戰
    • 與 BETA-內醯胺和 BETA-內醯胺酶抑制劑相關的生產複雜性

波特五力策略工具駕馭 BETA-內醯胺和 BETA-內醯胺酶抑制劑市場

波特的五力框架是了解 BETA-內醯胺藥物和 BETA-內醯胺酶抑制劑市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解外部對BETA-內醯胺藥物和BETA-內醯胺酶抑制劑市場的影響

外部宏觀環境因素在塑造BETA-內醯胺藥物和BETA-內醯胺酶抑制劑市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解BETA-內醯胺藥物/BETA-內醯胺酶抑制劑市場的競爭狀況

BETA-內醯胺藥物和 BETA-內醯胺酶抑制劑市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣BETA-內醯胺藥物和BETA-內醯胺酶抑制劑市場供應商的績效評估

FPNV定位矩陣是評估BETA-內醯胺和BETA-內醯胺酶抑制劑市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪 BETA-內醯胺和 BETA-內醯胺酶抑制劑市場的成功之路

BETA-內醯胺藥物和 BETA-內醯胺酶抑制劑市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地細菌感染疾病的盛行率增加
      • 政府對抗抗生素抗藥性的措施和計劃
      • 醫療保健專業人員和患者越來越意識到聯合治療的益處。
    • 抑制因素
      • 新藥監管要求嚴格、核准流程漫長
    • 機會
      • 與BETA-內醯胺抗生素共同開發新型BETA-內醯胺酶抑制劑
      • 減少抗生素生產對環境影響的永續製造方法
    • 任務
      • 與 BETA-內醯胺和 BETA-內醯胺酶抑制劑相關的生產複雜性
  • 市場區隔分析
    • 藥物類別：推動不同藥物類別 BETA-內醯胺和 BETA-內醯胺酶抑制劑的成長和功效的創新策略
    • 最終用戶：BETA-內醯胺和BETA-內醯胺酶抑制劑的全球市場開發：滿足醫院和專科中心需求的創新解決方案
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的BETA-內醯胺類藥物/BETA-內醯胺酶抑制劑市場

  • 碳青黴烯類
  • 頭孢菌素
  • 單環胺基類
  • 青黴素

第7章 BETA-內醯胺藥物與BETA-內醯胺酶抑制劑市場：依疾病分類

  • 血流感染疾病
  • 複雜性腹腔內感染疾病（cIAI）
  • 複雜性尿道感染(cUTI)
  • 院內肺炎
  • 呼吸道感染疾病
  • 皮膚感染疾病
  • 尿道感染（不包括 cUTI）

第8章 BETA-內醯胺藥物和BETA-內醯胺酶抑制劑市場：依給藥途徑

  • 靜脈
  • 口服

第9章依分銷管道分類的BETA-內醯胺藥物和BETA-內醯胺酶抑制劑市場

  • 醫院藥房
  • 零售藥房

第10章 BETA-內醯胺藥物和BETA-內醯胺酶抑制劑市場：依最終用戶分類

  • 診所
  • 醫院
  • 專業中心

第11章 BETA-內醯胺類藥物/BETA-內醯胺酶抑制劑依市場藥品類型分類

  • 在商店
  • 指定的

第12章 北美和南美BETA-內醯胺和BETA-內醯胺酶抑制劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太BETA-內醯胺和BETA-內醯胺酶抑制劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章歐洲、中東和非洲BETA-內醯胺藥物和BETA-內醯胺酶抑制劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Qpex Biopharma 獲得 BARDA 1000 萬美元津貼，用於推進 zelborbactam 的開發，以對抗抗藥性細菌
    • 歐盟委員會核准公司的 EMBLAVEO 用於治療多重抗藥性感染疾病
    • Benatrox Pharmaceuticals 與 Menarini Group 合作將頭孢吡肟坦尼硼巴坦商業化
    • Melinta Therapeutics 與 BARDA 合作開發兒科抗生素製劑
    • 丸紅株式會社與 Fobeni Healthcom 和 Meiji Seika 合作進行創新 BETA-內醯胺酶抑制劑 nacubactam 的臨床試驗
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Centrient Pharmaceuticals Netherlands BV
  • Cipla Ltd.
  • Creative Diagnostics
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Marubeni Corporation
  • Melinta Therapeutics, LLC
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Protech Telelinks
  • Qpex Biopharma, Inc. by Shionogi Inc.
  • Sanofi SA
  • SciClone Pharmaceuticals（Holdings）Limited
  • Sumitomo Pharma Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • TOKU-E
  • Venatorx Pharmaceuticals, Inc.
  • Viatris Inc.
  • Zai Lab Limited
Product Code: MRR-450A0628C441

The Beta Lactam & Beta Lactamase Inhibitors Market was valued at USD 26.33 billion in 2023, expected to reach USD 27.33 billion in 2024, and is projected to grow at a CAGR of 4.58%, to USD 36.02 billion by 2030.

The Beta Lactam & Beta Lactamase Inhibitors market is defined by its focus on antibiotics that include both beta lactam antibiotics and beta lactamase inhibitors, essential in combating bacterial infections by targeting and neutralizing the enzymes that confer bacterial resistance. The necessity of these compounds is underscored by the ongoing global challenge posed by antibiotic-resistant bacteria, driving demand in medical and pharmaceutical fields for their application in treating a wide array of bacterial infections. The end-use scope spans hospitals, clinics, and homecare settings, with the majority of demand emerging from regions with advanced healthcare infrastructure. Key growth factors influencing this market include increasing incidence of antibiotic-resistant infections, rising healthcare expenditure, and continuous R&D into novel drug formulations and combinations that enhance efficacy. There are opportunities in the expansion of affordable healthcare services and governmental initiatives to curb antibiotic resistance, as well as the adoption of advanced biotechnology in drug development. However, market growth may be challenged by stringent regulatory frameworks, high costs associated with drug development, and the potential side effects of antibiotics, deterring widespread adoption. The best areas for innovation include developing next-generation beta lactam drugs with broad-spectrum activity and minimal side effects, as well as exploring synergistic combinations that improve treatment efficiency. Investment in diagnostic tools for early detection of resistant strains can also drive market demand. Moreover, fostering collaborative research between pharmaceutical companies and research institutes can enhance insights into bacterial resistance, thus leading to groundbreaking solutions. The market's nature is dynamic, characterized by rapid advancements and a high degree of competition, requiring stakeholders to stay ahead with continuous innovation and strategic planning in product development and market penetration strategies.

KEY MARKET STATISTICS
Base Year [2023] USD 26.33 billion
Estimated Year [2024] USD 27.33 billion
Forecast Year [2030] USD 36.02 billion
CAGR (%) 4.58%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Beta Lactam & Beta Lactamase Inhibitors Market

The Beta Lactam & Beta Lactamase Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of bacterial infections globally
    • Government initiatives and programs to combat antibiotic resistance
    • Rising awareness among healthcare professionals and patients about the benefits of combination antibiotic therapies
  • Market Restraints
    • Stringent regulatory requirements and the lengthy approval process for new drugs
  • Market Opportunities
    • Development of novel beta-lactamase inhibitors in combination with beta lactam antibiotics
    • Sustainable manufacturing practices to reduce the environmental impact of antibiotic production
  • Market Challenges
    • Production complexities associated with beta lactam & beta lactamase inhibitors

Porter's Five Forces: A Strategic Tool for Navigating the Beta Lactam & Beta Lactamase Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Beta Lactam & Beta Lactamase Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Beta Lactam & Beta Lactamase Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Beta Lactam & Beta Lactamase Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Beta Lactam & Beta Lactamase Inhibitors Market

A detailed market share analysis in the Beta Lactam & Beta Lactamase Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Beta Lactam & Beta Lactamase Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Beta Lactam & Beta Lactamase Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Beta Lactam & Beta Lactamase Inhibitors Market

A strategic analysis of the Beta Lactam & Beta Lactamase Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Beta Lactam & Beta Lactamase Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca plc, Aurobindo Pharma Limited, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Centrient Pharmaceuticals Netherlands B.V., Cipla Ltd., Creative Diagnostics, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Marubeni Corporation, Melinta Therapeutics, LLC, Merck KGaA, Novartis AG, Pfizer Inc., Protech Telelinks, Qpex Biopharma, Inc. by Shionogi Inc., Sanofi SA, SciClone Pharmaceuticals (Holdings) Limited, Sumitomo Pharma Co., Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., TOKU-E, Venatorx Pharmaceuticals, Inc., Viatris Inc., and Zai Lab Limited.

Market Segmentation & Coverage

This research report categorizes the Beta Lactam & Beta Lactamase Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Carbapenem, Cephalosporins, Monobactam, and Penicillin.
  • Based on Disease, market is studied across Blood Stream Infection, Complicated Intra-Abdominal Infections (cIAI), Complicated Urinary Tract Infection (cUTI), Nosocomial Pneumonia, Respiratory Infection, Skin Infection, and Urinary Tract Infection (excluding cUTI).
  • Based on Route of Administration, market is studied across Intravenous and Oral.
  • Based on Distribution Channels, market is studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on End User, market is studied across Clinics, Hospitals, and Specialty Centers.
  • Based on Drug Type, market is studied across Over the Counter and Prescribed.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of bacterial infections globally
      • 5.1.1.2. Government initiatives and programs to combat antibiotic resistance
      • 5.1.1.3. Rising awareness among healthcare professionals and patients about the benefits of combination antibiotic therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulatory requirements and the lengthy approval process for new drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of novel beta-lactamase inhibitors in combination with beta lactam antibiotics
      • 5.1.3.2. Sustainable manufacturing practices to reduce the environmental impact of antibiotic production
    • 5.1.4. Challenges
      • 5.1.4.1. Production complexities associated with beta lactam & beta lactamase inhibitors
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Innovative strategies to drive growth and effectiveness in the diverse classes of beta lactam & beta lactamase inhibitors
    • 5.2.2. End User: Evolving global market of beta-lactam & beta-lactamase inhibitors: catering to hospitals, and specialty centers with innovative solutions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Beta Lactam & Beta Lactamase Inhibitors Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Carbapenem
  • 6.3. Cephalosporins
  • 6.4. Monobactam
  • 6.5. Penicillin

7. Beta Lactam & Beta Lactamase Inhibitors Market, by Disease

  • 7.1. Introduction
  • 7.2. Blood Stream Infection
  • 7.3. Complicated Intra-Abdominal Infections (cIAI)
  • 7.4. Complicated Urinary Tract Infection (cUTI)
  • 7.5. Nosocomial Pneumonia
  • 7.6. Respiratory Infection
  • 7.7. Skin Infection
  • 7.8. Urinary Tract Infection (excluding cUTI)

8. Beta Lactam & Beta Lactamase Inhibitors Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral

9. Beta Lactam & Beta Lactamase Inhibitors Market, by Distribution Channels

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Retail Pharmacies

10. Beta Lactam & Beta Lactamase Inhibitors Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Hospitals
  • 10.4. Specialty Centers

11. Beta Lactam & Beta Lactamase Inhibitors Market, by Drug Type

  • 11.1. Introduction
  • 11.2. Over the Counter
  • 11.3. Prescribed

12. Americas Beta Lactam & Beta Lactamase Inhibitors Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Beta Lactam & Beta Lactamase Inhibitors Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Beta Lactam & Beta Lactamase Inhibitors Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Qpex Biopharma receives USD 10 million BARDA award to advance xeruborbactam development in fight against drug-resistant bacteria
    • 15.3.2. European Commission approves Pfizer's EMBLAVEO for multidrug-resistant infections
    • 15.3.3. Venatorx Pharmaceuticals collaborates with Menarini Group to commercialize cefepime-taniborbactam
    • 15.3.4. Melinta Therapeutics partners with BARDA to develop pediatric antibiotic formulations
    • 15.3.5. Marubeni Corporation collaborates with Fobeni Healthcom and Meiji Seika for clinical trial of innovative B-lactamase inhibitor nacubactam
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AstraZeneca plc
  • 3. Aurobindo Pharma Limited
  • 4. Bio-Rad Laboratories, Inc.
  • 5. Bristol-Myers Squibb Company
  • 6. Centrient Pharmaceuticals Netherlands B.V.
  • 7. Cipla Ltd.
  • 8. Creative Diagnostics
  • 9. F. Hoffmann-La Roche AG
  • 10. GlaxoSmithKline PLC
  • 11. Marubeni Corporation
  • 12. Melinta Therapeutics, LLC
  • 13. Merck KGaA
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Protech Telelinks
  • 17. Qpex Biopharma, Inc. by Shionogi Inc.
  • 18. Sanofi SA
  • 19. SciClone Pharmaceuticals (Holdings) Limited
  • 20. Sumitomo Pharma Co., Ltd.
  • 21. Teva Pharmaceutical Industries Ltd.
  • 22. Thermo Fisher Scientific Inc.
  • 23. TOKU-E
  • 24. Venatorx Pharmaceuticals, Inc.
  • 25. Viatris Inc.
  • 26. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET DYNAMICS
  • TABLE 7. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY MONOBACTAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY BLOOD STREAM INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION (CUTI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY NOSOCOMIAL PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RESPIRATORY INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTION (EXCLUDING CUTI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PRESCRIBED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023